Publisher Summary This chapter focuses on the role played by ErbB receptors in cancer
progression. Cancer patients, whose tumors have alterations in ErbB1 or ErbB2, tend to
have a more aggressive disease, associated with parameters predicting a poor clinical
outcome. Based upon these clinical findings, ErbB receptors have become appealing
therapeutic targets. Over the past years, several approaches, including targeting with
antagonistic antibodies or small-molecule tyrosine kinase inhibitors, have been developed …